Received Sep 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
joint ache; Body ache; nausea; headache; fever; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of joint pain in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix with an associated reaction of injection site pain (1st dose received on an unknown date, refer case US2025AMR124367). On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, less than a day after receiving Shingrix, the patient experienced joint pain (Verbatim: joint ache), general body pain (Verbatim: Body ache), nausea (Verbatim: nausea), headache (Verbatim: headache) and fever (Verbatim: fever). The outcome of the joint pain, general body pain, nausea, headache and fever were resolved (duration 48 hrs). The reporter considered the joint pain, general body pain, nausea, headache and fever to be related to Shingrix. The company considered the joint pain, general body pain, nausea, headache and fever to be related to Shingrix. Linked case(s) involving the same patient: US2025AMR124367 Additional Information: GSK Receipt Date: 24-SEP-2025 The reporter stated be sure to plan on taking the day after getting the second shingles shot off. The patient was down all day with body, joint aches, nausea, headache. The patient had a fever of 100.7-degree F. The next day of vaccination, 48 hours later, patient was fine. This case was linked with case US2025AMR124423 and US2025AMR124422 reported by the same reporter, for different patient.; Sender's Comments: US-GSK-US2025AMR124423:Same reporter US-GSK-US2025AMR124367:same reporter diff dose
Test Name: Body temperature; Result Unstructured Data: (Test Result:100,Unit:degree F,Normal Low:,Normal High:)